Patricia Chalela1, Lucina Suarez2, Edgar Muñoz1, Kipling J Gallion1, Brad H Pollock3, Steven D Weitman4, Anand Karnad4, Amelie G Ramirez1. 1. Institute for Health Promotion Research The University of Texas Health Science Center at San Antonio 7411 John Smith Dr., Suite 1000 San Antonio, TX 78229. 2. Austin, Texas 78703. 3. Department of Epidemiology and Biostatistics The University of Texas Health Science Center at San Antonio 7703 Floyd Curl Ave., Mail Code 7933 San Antonio, TX 78229-3901. 4. The University of Texas Health Science Center at San Antonio Cancer Therapy & Research Center Institute for Drug Development 7979 Wurzbach Road, Room Z459 San Antonio, Texas 78229.
Abstract
BACKGROUND: Inclusion of minorities in clinical research is an essential step to develop novel cancer treatments, improve health care overall, understand potential differences in pharmacogenomics and address minorities' disproportionate cancer burden. However, Latinos and other minority groups continue to be critically underrepresented, particularly in early-phase clinical trials (EPCTs). The objective of the present study was to explore barriers and promoting factors influencing patients' decisions to enroll or not in early phase clinical trials (EPCTs) and identify areas for intervention to increase minority enrollment into clinical research. METHODS: An interviewer-administered survey was conducted with 100 cancer patients in the predominantly Latino region of South Texas. Exploratory factor analysis was conducted to identify underlying dimensions, and multiple logistic regression assessed significant factors that promote or deter patients enrollment to EPCTs. In addition, a separate subgroup mean analysis assessed differences by enrollment status and race/ethnicity. RESULTS: For one standard deviation increase in the importance given to the possibility of symptoms improvement, the predicted odds of refusing enrollment were 3.20 times greater (OR=3.20, 95% CI=1.06-9.71, p 0.040). Regarding barriers, among patients who considered fear/uncertainty of the new treatment a deterrent to enrollment, one standard deviation increase in agreement with these barriers was associated with a 3.60 increase (OR=3.60, 95% CI=1.30-9.97h, p 0.014) in the odds of not being enrolled in an EPCT. In contrast, non-enrolled patients were less likely (OR=0.14, 95% CI=0.05-0.44, p 0.001) to consider fatalistic beliefs as an important barrier. CONCLUSION: This study, one of the first to identify South Texas patients' barriers to enroll in EPCTs, highlights potential focal areas to increase participation of both minority and non-minority patients in clinical research. Culturally tailored interventions promoting patient-centered care and bilingual, culturally competent study teams could solve common barriers and enhance Latinos' likelihood of joining clinical trials. These interventions may simultaneously increase opportunities to involve patients and physicians in clinical trials, while ensuring the benefits of participation are equitably distributed to all patients.
BACKGROUND: Inclusion of minorities in clinical research is an essential step to develop novel cancer treatments, improve health care overall, understand potential differences in pharmacogenomics and address minorities' disproportionate cancer burden. However, Latinos and other minority groups continue to be critically underrepresented, particularly in early-phase clinical trials (EPCTs). The objective of the present study was to explore barriers and promoting factors influencing patients' decisions to enroll or not in early phase clinical trials (EPCTs) and identify areas for intervention to increase minority enrollment into clinical research. METHODS: An interviewer-administered survey was conducted with 100 cancerpatients in the predominantly Latino region of South Texas. Exploratory factor analysis was conducted to identify underlying dimensions, and multiple logistic regression assessed significant factors that promote or deter patients enrollment to EPCTs. In addition, a separate subgroup mean analysis assessed differences by enrollment status and race/ethnicity. RESULTS: For one standard deviation increase in the importance given to the possibility of symptoms improvement, the predicted odds of refusing enrollment were 3.20 times greater (OR=3.20, 95% CI=1.06-9.71, p 0.040). Regarding barriers, among patients who considered fear/uncertainty of the new treatment a deterrent to enrollment, one standard deviation increase in agreement with these barriers was associated with a 3.60 increase (OR=3.60, 95% CI=1.30-9.97h, p 0.014) in the odds of not being enrolled in an EPCT. In contrast, non-enrolled patients were less likely (OR=0.14, 95% CI=0.05-0.44, p 0.001) to consider fatalistic beliefs as an important barrier. CONCLUSION: This study, one of the first to identify South Texas patients' barriers to enroll in EPCTs, highlights potential focal areas to increase participation of both minority and non-minority patients in clinical research. Culturally tailored interventions promoting patient-centered care and bilingual, culturally competent study teams could solve common barriers and enhance Latinos' likelihood of joining clinical trials. These interventions may simultaneously increase opportunities to involve patients and physicians in clinical trials, while ensuring the benefits of participation are equitably distributed to all patients.
Entities:
Keywords:
Barriers; Cancer Patients; Clinical Trials; Early phase; Enrollment; Promoters
Authors: J G Ford; M W Howerton; S Bolen; T L Gary; G Y Lai; J Tilburt; M C Gibbons; C Baffi; R F Wilson; C J Feuerstein; P Tanpitukpongse; N R Powe; E B Bass Journal: Evid Rep Technol Assess (Summ) Date: 2005-06
Authors: Jean G Ford; Mollie W Howerton; Gabriel Y Lai; Tiffany L Gary; Shari Bolen; M Chris Gibbons; Jon Tilburt; Charles Baffi; Teerath Peter Tanpitukpongse; Renee F Wilson; Neil R Powe; Eric B Bass Journal: Cancer Date: 2008-01-15 Impact factor: 6.860
Authors: Jeffrey N Weitzel; Jessica Clague; Arelis Martir-Negron; Raquel Ogaz; Josef Herzog; Charité Ricker; Chelsy Jungbluth; Cheryl Cina; Paul Duncan; Gary Unzeitig; J Salvador Saldivar; Mary Beattie; Nancy Feldman; Sharon Sand; Danielle Port; Deborah I Barragan; Esther M John; Susan L Neuhausen; Garrett P Larson Journal: J Clin Oncol Date: 2012-12-10 Impact factor: 44.544
Authors: Amelie G Ramirez; Patricia Chalela; Lucina Suarez; Edgar Muñoz; Brad H Pollock; Steven D Weitman; Kipling J Gallion Journal: J Community Med Health Educ Date: 2012-09-24
Authors: R M Chamberlain; K A Winter; S Vijayakumar; A T Porter; M Roach; O Streeter; J D Cox; M L Bondy Journal: Int J Radiat Oncol Biol Phys Date: 1998-01-01 Impact factor: 7.038
Authors: Daphna Weissglas-Volkov; Carlos A Aguilar-Salinas; Elina Nikkola; Kerry A Deere; Ivette Cruz-Bautista; Olimpia Arellano-Campos; Linda Liliana Muñoz-Hernandez; Lizeth Gomez-Munguia; Maria Luisa Ordoñez-Sánchez; Prasad M V Linga Reddy; Aldons J Lusis; Niina Matikainen; Marja-Riitta Taskinen; Laura Riba; Rita M Cantor; Janet S Sinsheimer; Teresa Tusie-Luna; Päivi Pajukanta Journal: J Med Genet Date: 2013-03-15 Impact factor: 6.318
Authors: V Jenkins; D Farewell; L Batt; T Maughan; L Branston; C Langridge; L Parlour; V Farewell; L Fallowfield Journal: Br J Cancer Date: 2010-11-30 Impact factor: 7.640
Authors: S D Sackett; M E Brown; D M Tremmel; T Ellis; W J Burlingham; J S Odorico Journal: Transplant Rev (Orlando) Date: 2016-02-10 Impact factor: 3.943
Authors: Elizabeth G Moore; Myra Roche; Christine Rini; Edward W Corty; Zahra Girnary; Julianne M O'Daniel; Feng-Chang Lin; Giselle Corbie-Smith; James P Evans; Gail E Henderson; Jonathan S Berg Journal: Public Health Genomics Date: 2018-08-07 Impact factor: 2.000
Authors: Arthur E Frankel; Keith T Flaherty; George J Weiner; Robert Chen; Nilofer S Azad; Michael J Pishvaian; John A Thompson; Matthew H Taylor; Daruka Mahadevan; A Craig Lockhart; Ulka N Vaishampayan; Jordan D Berlin; David C Smith; John Sarantopoulos; Matthew Riese; Mansoor N Saleh; Chul Ahn; Eugene P Frenkel Journal: Oncologist Date: 2017-03-17
Authors: Yazed AlRuthia; Sultan Alghadeer; Bander Balkhi; Haya M Almalag; Hana Alsobayel; Faris Alodaibi; Fakhr Alayoubi; Amal S Alkhamali; Samar Alshuwairikh; Futoun N Alqahtani; Hisham Alsanawi Journal: Saudi Pharm J Date: 2019-06-10 Impact factor: 4.330